Our Portfolio
£425k Invested
6 Active Portfolio Companies
£4.5m Raised in Leveraged Investment
Our Active Investments
We are excited about the potential the following companies have to address significant unmet needs in prostate cancer.
Proven Connect’s highly experienced leadership team and Translational Scientific Advisory Committee carry out rigorous due diligence on all companies that are included in our portfolio.
We ensure companies can demonstrate their commercial viability and technical rigour as well as their ability to meet a significant patient need.
Proven Connects wrap-around programme of support, in terms of mentorship, patient and clinical engagement and business advice, is designed to increase investors confidence in a companies ability to succeed.
Proven Connect will source a wide range of companies working in diagnostics, therapeutics and care of patients from our networks with pharma, CRO’s, TTO’s and other research organisations.
Explore opportunities with Proven
- Co-investing with Proven Connect, VC’s, Angel investors and Innovate UK at seed level
- Explore opportunities for follow on investments with later stage companies
- Work with Proven Connect to carry out due diligence
Interested in supporting us?
Early-stage biotechs rely on investment from private individuals, family offices and VC’s now more than ever. Proven Connect has selected to work with the following companies based upon their technology, team, commercial planning and most importantly the potential impact they can have on patients. If you are interested in supporting any of the companies featured below, please contact us today.
Proven Connect is looking for impact investors who are seeking new investment opportunities in healthcare that have the clinical and commercial support of experts working in prostate cancer.
I believe this is a tremendously exciting new development in the Cancer space, and in the UK life science ecosystem. The profile of company/projects you are targeting will fall ideally into the remit of many larger VC firms as the portfolio matures. Indeed, I am keen to keep our dialogue active as your projects grows, and we can begin to look to invest in some of the opportunities. This is a wonderful initiative and congratulations in getting it off the ground.
Dr Allan Marchington
Managing Director, Head of Life Sciences, Intermediate Capital Group
Disclaimer for the website
Information about companies on the Proven Connect website are provided for information and discussion purposes only and has not been audited or independently verified and no information herein will form the basis of any contract. Neither Proven Connect nor any of its personnel makes any representation, or gives any warranty, in each case express or implied, as to the fairness, accuracy, reasonableness, completeness, or correctness of this presentation or its contents. To the maximum extent permitted by law, neither Proven Connect nor any of its personnel shall be liable (including for negligence) for any direct, indirect, or consequential loss, damage, cost, or expense arising out of or in connection with any person’s use of or reliance on this presentation.